The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Laughlin, S.K., Clark, M.P., Djung, J.F., Golebiowski, A., Brugel, T.A., Sabat, M., Bookland, R.G., Laufersweiler, M.J., Vanrens, J.C., Townes, J.A., De, B., Hsieh, L.C., Xu, S.C., Walter, R.L., Mekel, M.J., Janusz, M.J.(2005) Bioorg Med Chem Lett 15: 2399-2403
- PubMed: 15837333
- DOI: https://doi.org/10.1016/j.bmcl.2005.02.066
- Primary Citation of Related Structures:
1YW2 - PubMed Abstract:
4-Aryl-3-pyridyl and 4-aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel isoxazolone five-membered heterocyclic core are described. Many showed sub-micromolar activity against lipopolysaccharide-induced TNF-alpha production.
Organizational Affiliation:
Health Care Research Center, Procter and Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, OH 45040, USA.